Dupilumab, a monoclonal antibody blocking IL-4Rα (Figure 3), has been shown to be effective as a treatment of moderate-to-severe AD and moderate-to-severe asthma (84, 85). This evidence concerns the gene IL4R and Alzheimer disease.